HomeNewsTrendsHealthOmicron subvariant BA.2 may cause severe disease, lab study suggests

Omicron subvariant BA.2 may cause severe disease, lab study suggests

The yet-to-be peer-reviewed findings, recently posted on the preprint repository BioRxiv, show that the BA.2 sub variant may have features that make it as capable of causing serious illness as older coronavirus variants.

February 18, 2022 / 18:49 IST
Image Source: Reuters

The BA.2 subvariant of the Omicron coronavirus variant is not only faster at spreading, but may also cause more severe disease, a lab study suggests.

The yet-to-be peer-reviewed findings, recently posted on the preprint repository BioRxiv, show that the BA.2 sub variant may have features that make it as capable of causing serious illness as older coronavirus variants.

On Thursday, the World Health Organization (WHO) said while BA.2 is more tranmsissible than BA.1, the subvariant is not more severe.

"Among all subvariants, BA.2 is more transmissible than BA.1. However, there is no difference in terms of severity," Maria Van Kerkhova, COVID-19 Technical Lead at WHO said in a video.

In the latest study, a Japanese team led by researchers from the University of Tokyo found that similar to BA.1, BA.2 subvariant of Omicron appears to largely escape the immunity induced by COVID-19 vaccines.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"Neutralisation experiments show that the vaccine-induced humoral immunity fails to function against BA.2 like BA.1," the authors of the study said.

Omicron was first reported from Botswana and South Africa in November, 2021. Its BA.1 sub variant has since rapidly spread across the world and outcompeted other variants such as Delta.

As of February this year, another subvariant of Omicron, the BA.2 lineage, has been detected in multiple countries such as Denmark and the UK.

BA.2 has started outcompeting BA.1, suggesting that it is more transmissible than the original Omicron, the researchers said.

"Although BA.2 is considered as an Omicron variant, its genomic sequence is heavily different from BA.1, which suggests that the virological characteristics of BA.2 is different from that of BA.1," the authors noted.

When the researchers infected hamsters with BA.2 and BA.1, the animals infected with BA.2 got sicker and had worse lung function.

In tissues samples, the lungs of BA.2-infected hamsters had more damage than those infected by BA.1, they said.

"Our investigations using a hamster model showed that the pathogenicity of BA.2 is similar to that of an ancestral B.1.1 and higher than that of BA.1," the authors noted.

Similar to the original Omicron, BA.2 was resistant to antibodies in the blood of people who had been vaccinated against COVID-19.

It was also resistant to the antibodies of people who had been infected with the earlier variants of SARS-CoV-2, according to the researchers.

BA.2 was almost completely resistant to some monoclonal antibody treatments used to treat COVID-19 infection, they said.

"Together with a higher effective reproduction number and pronounced immune resistance of BA.2, it is evident that the spread of BA.2 can be a serious issue for global health in the near future," the authors added.

The reproduction number is a measure of transmission -- the average number of people infected by one infected person.

PTI
first published: Feb 18, 2022 06:49 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347